Jacob D Kohlenberg1, Marcello C Laurenti2, Aoife M Egan1, Daniel Schembri Wismayer1, Kent R Bailey3, Claudio Cobelli4, Chiara Dalla Man5, Adrian Vella6. 1. Division of Endocrinology, Diabetes and Metabolism, Mayo Clinic College of Medicine, Rochester, MN, USA. 2. Biomedical Engineering and Physiology Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN, USA. 3. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA. 4. Department of Women's and Children's Health, University of Padova, Padova, Italy. 5. Department of Information Engineering, University of Padova, Padova, Italy. 6. Division of Endocrinology, Diabetes and Metabolism, Mayo Clinic College of Medicine, Rochester, MN, USA. vella.adrian@mayo.edu.
Abstract
AIMS/HYPOTHESIS: People with isolated impaired fasting glucose (IFG) have normal beta cell function. We hypothesised that an increased glucose threshold for beta cell secretion explains IFG. METHODS: We used graded glucose infusion to examine the relationship of insulin secretion rate (ISR) and glucagon secretion rate (GSR) with rising glucose. We studied 39 non-diabetic individuals (53 ± 2 years, BMI 30 ± 1 kg/m2), categorised by fasting glucose and glucose tolerance status. After an overnight fast, a variable insulin infusion was used to maintain glucose at ~4.44 mmol/l (07:00 to 08:30 hours). At 09:00 hours, graded glucose infusion commenced at 1 mg kg-1 min-1 and doubled every 60 min until 13:00 hours. GSR and ISR were calculated by nonparametric deconvolution from concentrations of glucagon and C-peptide, respectively. RESULTS: The relationship of ISR with glucose was linear and the threshold for insulin secretion in isolated IFG did not differ from that in people with normal fasting glucose and normal glucose tolerance. GSR exhibited a single-exponential relationship with glucose that could be characterised by G50, the change in glucose necessary to suppress GSR by 50%. G50 was increased in IFG compared with normal fasting glucose regardless of the presence of impaired or normal glucose tolerance. CONCLUSIONS/ INTERPRETATION: These data show that, in non-diabetic humans, alpha cell dysfunction contributes to the pathogenesis of IFG independently of defects in insulin secretion. We also describe a new index that quantifies the suppression of glucagon secretion by glucose.
AIMS/HYPOTHESIS: People with isolated impaired fasting glucose (IFG) have normal beta cell function. We hypothesised that an increased glucose threshold for beta cell secretion explains IFG. METHODS: We used graded glucose infusion to examine the relationship of insulin secretion rate (ISR) and glucagon secretion rate (GSR) with rising glucose. We studied 39 non-diabetic individuals (53 ± 2 years, BMI 30 ± 1 kg/m2), categorised by fasting glucose and glucose tolerance status. After an overnight fast, a variable insulin infusion was used to maintain glucose at ~4.44 mmol/l (07:00 to 08:30 hours). At 09:00 hours, graded glucose infusion commenced at 1 mg kg-1 min-1 and doubled every 60 min until 13:00 hours. GSR and ISR were calculated by nonparametric deconvolution from concentrations of glucagon and C-peptide, respectively. RESULTS: The relationship of ISR with glucose was linear and the threshold for insulin secretion in isolated IFG did not differ from that in people with normal fasting glucose and normal glucose tolerance. GSR exhibited a single-exponential relationship with glucose that could be characterised by G50, the change in glucose necessary to suppress GSR by 50%. G50 was increased in IFG compared with normal fasting glucose regardless of the presence of impaired or normal glucose tolerance. CONCLUSIONS/ INTERPRETATION: These data show that, in non-diabetic humans, alpha cell dysfunction contributes to the pathogenesis of IFG independently of defects in insulin secretion. We also describe a new index that quantifies the suppression of glucagon secretion by glucose.
Authors: Anu Sharma; Ron T Varghese; Meera Shah; Chiara Dalla Man; Claudio Cobelli; Robert A Rizza; Kent R Bailey; Adrian Vella Journal: J Clin Endocrinol Metab Date: 2018-01-01 Impact factor: 5.958
Authors: William C Knowler; Elizabeth Barrett-Connor; Sarah E Fowler; Richard F Hamman; John M Lachin; Elizabeth A Walker; David M Nathan Journal: N Engl J Med Date: 2002-02-07 Impact factor: 91.245
Authors: Fumiaki Imamura; Kenneth J Mukamal; James B Meigs; José A Luchsinger; Joachim H Ix; David S Siscovick; Dariush Mozaffarian Journal: Am J Epidemiol Date: 2013-05-24 Impact factor: 4.897
Authors: Richa Saxena; Marie-France Hivert; Claudia Langenberg; Toshiko Tanaka; James S Pankow; Peter Vollenweider; Valeriya Lyssenko; Nabila Bouatia-Naji; Josée Dupuis; Anne U Jackson; W H Linda Kao; Man Li; Nicole L Glazer; Alisa K Manning; Jian'an Luan; Heather M Stringham; Inga Prokopenko; Toby Johnson; Niels Grarup; Trine W Boesgaard; Cécile Lecoeur; Peter Shrader; Jeffrey O'Connell; Erik Ingelsson; David J Couper; Kenneth Rice; Kijoung Song; Camilla H Andreasen; Christian Dina; Anna Köttgen; Olivier Le Bacquer; François Pattou; Jalal Taneera; Valgerdur Steinthorsdottir; Denis Rybin; Kristin Ardlie; Michael Sampson; Lu Qi; Mandy van Hoek; Michael N Weedon; Yurii S Aulchenko; Benjamin F Voight; Harald Grallert; Beverley Balkau; Richard N Bergman; Suzette J Bielinski; Amelie Bonnefond; Lori L Bonnycastle; Knut Borch-Johnsen; Yvonne Böttcher; Eric Brunner; Thomas A Buchanan; Suzannah J Bumpstead; Christine Cavalcanti-Proença; Guillaume Charpentier; Yii-Der Ida Chen; Peter S Chines; Francis S Collins; Marilyn Cornelis; Gabriel J Crawford; Jerome Delplanque; Alex Doney; Josephine M Egan; Michael R Erdos; Mathieu Firmann; Nita G Forouhi; Caroline S Fox; Mark O Goodarzi; Jürgen Graessler; Aroon Hingorani; Bo Isomaa; Torben Jørgensen; Mika Kivimaki; Peter Kovacs; Knut Krohn; Meena Kumari; Torsten Lauritzen; Claire Lévy-Marchal; Vladimir Mayor; Jarred B McAteer; David Meyre; Braxton D Mitchell; Karen L Mohlke; Mario A Morken; Narisu Narisu; Colin N A Palmer; Ruth Pakyz; Laura Pascoe; Felicity Payne; Daniel Pearson; Wolfgang Rathmann; Annelli Sandbaek; Avan Aihie Sayer; Laura J Scott; Stephen J Sharp; Eric Sijbrands; Andrew Singleton; David S Siscovick; Nicholas L Smith; Thomas Sparsø; Amy J Swift; Holly Syddall; Gudmar Thorleifsson; Anke Tönjes; Tiinamaija Tuomi; Jaakko Tuomilehto; Timo T Valle; Gérard Waeber; Andrew Walley; Dawn M Waterworth; Eleftheria Zeggini; Jing Hua Zhao; Thomas Illig; H Erich Wichmann; James F Wilson; Cornelia van Duijn; Frank B Hu; Andrew D Morris; Timothy M Frayling; Andrew T Hattersley; Unnur Thorsteinsdottir; Kari Stefansson; Peter Nilsson; Ann-Christine Syvänen; Alan R Shuldiner; Mark Walker; Stefan R Bornstein; Peter Schwarz; Gordon H Williams; David M Nathan; Johanna Kuusisto; Markku Laakso; Cyrus Cooper; Michael Marmot; Luigi Ferrucci; Vincent Mooser; Michael Stumvoll; Ruth J F Loos; David Altshuler; Bruce M Psaty; Jerome I Rotter; Eric Boerwinkle; Torben Hansen; Oluf Pedersen; Jose C Florez; Mark I McCarthy; Michael Boehnke; Inês Barroso; Robert Sladek; Philippe Froguel; James B Meigs; Leif Groop; Nicholas J Wareham; Richard M Watanabe Journal: Nat Genet Date: 2010-01-17 Impact factor: 38.330